CCT128930 is a potent, ATP-competitive and selective inhibitor of Akt2 (IC50: 6 nM). CCT128930 has been shown to exhibit marked antiproliferative activity against PTEN-deficient human tumor cell lines including U87MG human glioblastoma cells, LNCaP human prostate cancer cells and PC3 human prostate cancer cells (GI50's: U87MG = 6.3 μM, LNCaP = 0.35 μmol/L and PC3 = 1.9 μmol/L). Furthermore, CCT128930 causes a G1 arrest in PTEN-null U87MG human glioblastoma cells and Akt pathway blockade.
Store at -20° C
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
Download SDS (MSDS)
Certificate of Analysis
Adobe Acrobat Reader is required to reliably view, print and comment on PDF documents
CCT128930 (CAS 885499-61-6)
See how others have used CCT128930 (CAS 885499-61-6). Click on the entry to view the PubMed entry
Do you have an Akt specific inhibitor that is not covered by a patent or that it will be soon generic?
Asked by: shoshi
Thank you for your question. We offer quite a few chemicals that are Akt Inhibitors. You can find them on our website.
If you have any further questions, please contact our European Technical Service team. You can reach them by phone at Toll Free: +49 6221 4503 0, by email at: [email protected] or by live chat directly on our website, www.scbt.com
Rated 5 out of
Wang FZ; et alWang FZ; et al. (PubMed ID: 24793486) determined that higher doses of CCT128930 increased apoptosis and activation of caspase-3, caspase-9, and PARP. -SCBT Publication Review
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn